Zhejiang Huahai Pharmaceutical (600521) announced on the evening of July 8 that its subsidiary, Huao Tai and Huabo Biopharmaceutical, have received the "Drug Clinical Trial Approval Notice" for HB0046 injection issued by the National Medical Products Administration.
华海药业：HB0046注射液获临床试验批准通知书
Zhejiang Huahai Pharmaceutical: HB0046 injection received clinical trial approval notice.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.